Furthermore, a sample set containing 223 clinically validated primary malignant tumors was subdivided into basal group including 99 samples characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and HER-2 expression in immunohistochemical evaluations [23], and non-basal group with the rest 124 samples. Here, ERBB2 is linked to cancer.